Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
3,518 total articles
Cantor Fitzgerald initiated coverage of BitGo Holdings (NYSE: BTGO) with an Overweight rating and a $18 price target, citing the company’s role as a software and infrastructure provider to institutional and corporate digital-asset activity. The firm recognizes BitGo’s low gross profit margins but views the current share price as presenting an attra…
Citizens has initiated coverage on EquipmentShare.com (NASDAQ: EQPT) with a Market Outperform rating and a $42.00 price objective, implying roughly 24% upside from the prevailing share price of $33.77. The research note points to the company's rapid organic expansion in U.S. construction equipment rentals, its T3 technology platform and the OWN Pro…
HSBC upgraded Cognex to Buy from Hold and lifted its price target to $68, pointing to a marked improvement in margins driven by SG&A reductions, portfolio moves and a 2026 cost-reduction roadmap. Cognex reported fourth-quarter revenue and profit-margin gains that prompted several brokerages to revise price targets and ratings across the stock.
Goldman Sachs has initiated coverage of BitGo Holdings (NYSE: BTGO) with a Neutral rating and a price target of $11.50, reflecting roughly 10% upside from the current share price of $10.76. The bank's valuation is anchored to a multiple of adjusted EBITDA and acknowledges BitGo's profitable trailing twelve-month performance, while calling out reven…
Morgan Stanley upgraded Truist Financial (NYSE: TFC) to Overweight from Equalweight and increased its price target to $69, driven by what it describes as a large excess-capital position and scope for accelerated capital deployment through loans and buybacks. The bank reported a mixed quarter with earnings and revenue slightly below expectations and…
Morgan Stanley moved Veeva Systems (VEEV) from Underweight to Equalweight while trimming its price target to $205 from $222. The upgrade reflects a shift in sentiment since a June 2023 downgrade, even as divergent analyst views and a newly announced $2 billion buyback program highlight differing assessments of the company’s growth durability, compe…
Baird has launched coverage of Caris Life Sciences (NASDAQ: CAI) with an outperform rating and a $26 price target, implying roughly 26% upside from the current share price. The initiation comes amid a steep share-price decline over the past six months, while preliminary fourth-quarter and full-year 2025 results topped analyst and FactSet consensus.
Goldman Sachs has initiated research coverage on EquipmentShare (EQPT) with a Buy rating and a $51 price objective, implying roughly 51% upside from the stock's $33.77 level. The bank cited the company's product mix, a capital-light financing model, and concentration in large projects and national accounts as drivers for above-peer growth. Goldman …
Baird has initiated coverage of EquipmentShare.com (NASDAQ: EQPT) with an Outperform rating and a $63 price target, implying roughly 86% upside from the current share price of $33.77. The firm highlighted the company’s capital-light growth model, the T3 technology platform and plans to expand 70-80 branches annually through 2030. Recent market acti…
Raymond James moved Marsh (NYSE: MRSH) from Outperform to Strong Buy while trimming its price target to $225 from $240, arguing the stock is experiencing a valuation reset rather than a deterioration in near-term fundamentals. The firm pointed to Marsh’s resilient earnings profile, margin expansion track record, and the strongest credit signal amon…
Rothschild Redburn lowered its rating on Warner Bros. Discovery to Neutral from Buy and lifted its price target to $31.00 from $28.00, citing Netflix as the most probable buyer and limited likelihood of significantly higher offers from Paramount. The firm pegs the remaining Discovery Global unit at $2.80 per WBD share and applies a 4.5x EBITDA mult…
Rothschild Redburn reduced its rating on ICON plc to Neutral from Buy and cut its price target to $100 from $226 after the company disclosed an internal accounting investigation into revenue recognition covering fiscal years 2023 through 2025. Preliminary findings indicate potential overstatements of under 2% for each of fiscal 2023 and 2024; ICON …
Baird has begun formal coverage of Tempus AI Inc (NASDAQ:TEM), assigning an Outperform rating with a $59.00 price objective, roughly 14% above the current share price of $51.95. The research note accompanies a Speculative Risk designation and comes as Tempus reports preliminary, unaudited commercial milestones including a record total contract valu…
Baird has begun coverage of Guardant Health (NASDAQ: GH) with an Outperform rating and a $120 price target, implying roughly 14% upside from the prevailing share price. The firm attached a Speculative Risk designation to the call and highlighted Guardant’s position in therapy-selection testing and pipeline optionality, while noting concerns about S…
Baird has initiated coverage of Grail, Inc. (NASDAQ: GRAL) with an Outperform rating and a $113.00 price target, implying roughly 16% upside from the referenced share price of $97.50. The firm classified the stock as Speculative Risk and pointed to clinical and regulatory milestones - including an NHS-Galleri study readout and a possible FDA decisi…
Citizens initiated coverage of Immutep Limited (NASDAQ: IMMP) with a Market Outperform rating and a $6 price target, pointing to substantial upside from the stock's recent price of $2.64. The analyst cited clinical data supporting efti's immunostimulatory activity, an ongoing Phase 3 NSCLC trial, and a solid cash position, while noting valuation an…
JPMorgan has begun coverage of Marqeta Inc. (MQ) with an Overweight rating and a $6.00 price target, signaling material upside from the stock's recent trading level. The firm highlights projected gross profit expansion and strength in buy now, pay later volume while acknowledging profitability challenges and customer concentration risks tied to Cas…
Compass Point upgraded Upstart Holdings Inc (UPST) from Sell to Neutral and lifted its price target to $30 from $20, aligning the target with the stock's recent trading level. The adjustment follows Upstart's fourth-quarter 2025 results and the company’s 2025-2028 guidance, which includes a roughly 35% revenue compound annual growth rate and a term…
UBS has raised its rating on SSP Group Plc. to Buy from Neutral and increased its price target to GBP2.45 from GBP1.80, flagging an improved outlook for cash generation and several potential upside catalysts alongside recently reported stronger financial results for the second half of 2025. The bank projects material free cash flow growth through 2…
UBS upgraded Southwest Airlines (LUV) to Buy from Neutral and raised its price target to $73 from $51, pointing to greater-than-anticipated revenue potential from extra-legroom seating, assigned seats, and checked-bag fees. The bank projects these initiatives could add roughly $4.25 to $4.50 in incremental EPS at full run-rate by fiscal 2027, and h…
Roth/MKM has initiated coverage of Karooooo Ltd. (NASDAQ: KARO) with a buy recommendation and a $62.00 price target. The brokerage sees the fleet management software provider sustaining mid-teens growth, supported by market share in South Africa, underpenetrated product lines such as AI cameras and tracking tags, and accelerating subscription metri…
Jefferies has begun coverage of Foghorn Therapeutics Inc. (NASDAQ: FHTX) with a Buy rating and a $12.00 price target, down from an earlier $14.00. The company, trading near $5.55 with a market capitalization of about $325 million, is being watched for a mid-2026 phase 1 readout of its SMARCA2 inhibitor FHD-909. Multiple brokerages have issued or re…
RBC Capital has initiated coverage of AXA SA with an Outperform rating and a EUR 48.00 price target, citing the insurer's multi-year business transformation toward technical insurance and fee-based earnings. The research note points to improved profitability, reduced earnings volatility, and a valuation gap versus European peers that may present up…
Jefferies has reaffirmed a Buy rating on Albemarle with a $230.00 price target, implying roughly an 18% upside from the stock's current price of $166.35. The firm highlights shifting price behavior in the lithium market and expects Albemarle to return to profitability, while other firms including Oppenheimer have also adjusted their outlooks upward…
Jefferies moved Enbridge Inc. (ENB) from Buy to Hold while increasing its price target to C$76.00 from C$71.00. The firm pointed to robust fourth-quarter EBITDA, progress on Venezuela projects and potential data center opportunities, but signaled that the stock's recent re-rating and relative valuation versus peers limit upside. Enbridge reported s…
